The BTK inhibitor ibrutinib occupies an important position in lymphoma treatment because it brings a survival hope for patients with B-cell lymphoma, and promotes development of a chemotherapy-free era for such patients. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.